Drug Trial Radar · NCT07077395
Finding Links Between Hot flASHes and CardioVascular Disease
Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Jun 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?
Conditions
- Menopause-related Hot Flashes
Interventions
elinzanetant - reference formulationDrug
elinzanetant 120 mg daily x 12 weeks
placeboDrug
placebo daily x 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- brachial artery flow mediated dilationTime frame: 12 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.